What is the recommended dosing regimen of Yaz (drospirenone/ethinyl estradiol) for acne treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yaz Dosage for Acne Treatment

For acne treatment, Yaz should be dosed as one tablet daily for 24 consecutive days of active hormone (3 mg drospirenone/0.02 mg ethinyl estradiol), followed by 4 days of inert tablets, taken at the same time each day in a continuous 28-day cycle. 1

Specific Dosing Instructions

The FDA-approved regimen consists of 1:

  • 24 light pink active tablets (each containing 3 mg drospirenone + 0.02 mg ethinyl estradiol)
  • 4 white inert tablets
  • Total cycle length: 28 days

Starting the Medication

You have two options for initiating therapy 1:

Day 1 Start (Preferred for immediate effect):

  • Begin on the first day of menstrual bleeding
  • Contraceptive effect is immediate
  • No backup contraception needed

Sunday Start:

  • Begin on the first Sunday after menstrual period starts
  • Requires backup contraception for the first 7 days
  • Use non-hormonal contraception during this time

Administration Details

  • Take tablets at the same time daily (preferably after evening meal or bedtime) 1
  • Can be taken with or without food 1
  • Must follow the order on the blister pack 1
  • Begin each new pack the day after finishing the 4 inert tablets, regardless of bleeding status 1

Evidence Supporting This Regimen

The 2024 American Academy of Dermatology guidelines conditionally recommend combined oral contraceptives for acne treatment based on moderate-certainty evidence 2. Drospirenone/ethinyl estradiol is one of four FDA-approved COCs specifically indicated for acne 2.

Clinical efficacy data demonstrates:

  • 46-57% reduction in total acne lesions by 6 months 3, 4
  • 52-53% reduction in both inflammatory and non-inflammatory lesions 5, 3
  • Approximately 3-fold greater odds of achieving "clear" or "almost clear" skin versus placebo 3, 4
  • Mean 79.9% reduction in total acne lesion count at cycle 6 6

Critical Patient Selection Criteria

Yaz is indicated ONLY for 1:

  • Women ≥14 years of age who have achieved menarche
  • Those who desire oral contraception as their birth control method
  • Moderate acne vulgaris with no contraindications to COC therapy

Absolute contraindications include 1:

  • Age >35 years who smoke (cardiovascular risk)
  • Renal impairment or adrenal insufficiency (hyperkalemia risk with drospirenone)
  • History of or high risk for venous/arterial thromboembolism
  • Uncontrolled hypertension or hypertension with vascular disease 2
  • Liver disease or liver tumors
  • Pregnancy or suspected pregnancy

Important Safety Considerations

Hyperkalemia monitoring: Drospirenone has antimineralocorticoid activity. While routine potassium monitoring is not required in healthy patients 2, check serum potassium during the first treatment cycle in women taking medications that increase potassium (ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, heparin) 1.

Cardiovascular risks: The absolute VTE risk remains low (approximately 10 per 10,000 person-years for drospirenone-containing COCs) but is higher than non-users 2. This risk is still substantially lower than pregnancy-associated VTE risk (5-20 per 10,000 person-years) 2.

Duration of Treatment

While the FDA label does not specify maximum treatment duration for acne 1, clinical trials demonstrating efficacy used 6-cycle (6-month) treatment periods 3, 7, 4. The 2024 AAD guidelines emphasize that acne patients with psychosocial burden or scarring should be considered for more aggressive therapy 2.

Common Pitfall to Avoid

Do not prescribe Yaz solely for acne treatment if the patient does not want or cannot use oral contraception 1. The FDA indication explicitly requires that patients desire contraception—this is both a regulatory requirement and reflects the risk-benefit analysis where contraceptive benefit justifies the cardiovascular and thrombotic risks of COC therapy.

Related Questions

What are the dosing recommendations and prescribing guidelines for Yaz (drospirenone 3 mg/ethinyl estradiol 0.02 mg), including contraindications and missed‑tablet management?
What is the best oral contraceptive pill for treating acne in an adolescent girl?
How long does it take for acne to improve with combined oral contraceptive (COC) therapy?
Can the low‑dose combined oral contraceptive micropill (≈20 µg ethinyl estradiol with a progestin) be prescribed solely for acne treatment in women of reproductive age?
In a reproductive‑age woman taking Slynd (drospirenone‑only oral contraceptive) for dysmenorrhea who developed facial, chest, and back acne after 5–6 months, does the medication improve acne?
Should piperacillin‑tazobactam be stopped and how long should vancomycin be continued in a patient with L4‑L5 discitis caused by Staphylococcus aureus susceptible to vancomycin who has been receiving both antibiotics for five days?
What are the evidence‑based strategies to prevent pressure ulcers in hospitalized patients?
What does a positive hepatitis A antibody with a negative IgM result indicate about infection status and need for treatment?
For a patient with Staphylococcus aureus causing L4‑L5 discitis, which antibiotic—clindamycin (MIC 0.25 µg/mL) or linezolid (MIC 2 µg/mL)—would be the preferred choice?
What are the diagnostic criteria for spontaneous bacterial peritonitis in a patient with ascites?
What is the recommended dosage and application schedule for Clindoxyl (clindamycin 1% and benzoyl peroxide 5% topical gel)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.